Annovis Bio Inc SEC Filings

A director of Annovis Bio, Inc. (ANVS) reported several open-market purchases of the company’s common stock. On 11/24/2025, the director bought blocks of Annovis Bio common shares at prices of $4.13, $3.85, $4.14, and $4.15 per share, each coded as a purchase transaction.

Following these transactions, the director beneficially owns 2,519,739 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power. The filing confirms the director’s status and that the report is filed for a single reporting person.

Annovis Bio, Inc. (ANVS) reported an insider stock purchase by a director. On 11/21/2025, the reporting person bought 10,000 shares of common stock at $3.49 per share and another 10,000 shares at $3.50 per share. After these transactions, the director beneficially owned 2,490,539 shares of Annovis Bio common stock directly. In addition, 223,357 shares are held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.

Annovis Bio, Inc. director reported purchasing 15,000 shares of common stock at $2.11 per share on 11/14/2025.

After this transaction, the director beneficially owns 2,470,539 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust, over which the reporting person has voting and investment power.

Annovis Bio (ANVS) filed its Q3 2025 10‑Q reporting continued operating losses and a going‑concern warning. The company posted a Q3 net loss of $7.3 million as research and development rose to $6.3 million with spending tied to its 6‑month Alzheimer’s trial and a Parkinson’s open‑label extension. General and administrative costs fell to $1.1 million. Cash and cash equivalents were $15.3 million, and warrant liability measured at fair value was $299,000.

Year‑to‑date, the net loss was $19.0 million, with higher interest income reflecting cash raised earlier in the year. Management concluded that existing cash is not sufficient for the period through one year after this report, indicating substantial doubt about the company’s ability to continue as a going concern, and plans to seek additional capital.

Financing activity included a February 2025 underwritten offering of 5.3 million units at $4.00 per unit (net proceeds $19.3 million) and sales under an ATM program. Subsequent to quarter‑end, the company raised $5.5 million in a registered direct offering on October 10, 2025 and $3.1 million on October 26, 2025. Shares outstanding were 20,187,904 at September 30, 2025; as of November 12, 2025, outstanding shares were 26,502,889.

Annovis Bio (ANVS) reported an insider share purchase by President & CEO and Director Maria Maccecchini. On 10/28/2025, she acquired 97,561 shares of common stock at $2.05 per share.

Following the transaction, she beneficially owns 1,212,020 shares, held directly. This filing reflects a personal share acquisition by a senior executive.

Annovis Bio (ANVS) — insider transaction. A director reported purchasing 975,610 shares of common stock at $2.05 on 10/28/2025 (Transaction Code P). Following the trade, the filer reported 2,455,539 shares held directly and 223,357 shares held indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The filing notes the reporting person has voting and investment power over the trust-held shares.

Annovis Bio (ANVS) reported an insider transaction on a Form 4. Director Claudine Bruck exercised a stock option and acquired 7,142 shares of common stock at $0.14 per share on 09/10/2025 (transaction code M).

Following the transaction, her directly held common stock totaled 13,709 shares. The option exercised had been exercisable since 09/18/2016 and carried an expiration date of 09/18/2025, and the derivative position reported after the exercise was 0.